Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda

Nakasujja, Noeline; Skolasky, Richard L.; Musisi, Seggane; Allebeck, Peter; Robertson, Kevin; Ronald, Allan; Katabira, Elly; Clifford, David B.; Sacktor, Ned
January 2010
BMC Psychiatry;2010, Vol. 10, p44
Academic Journal
Background: Among patients with HIV infection, depression is the most frequently observed psychiatric disorder. The presence of depressive symptoms and cognitive dysfunction among HIV patients has not been well studied in Sub- Saharan Africa. Initiation of highly active antiretroviral therapy (HAART) may have an effect on the prevalence and the change over time of depression symptoms and cognitive impairment among HIV-positive individuals. Methods: We recruited 102 HIV-positive individuals at risk of cognitive impairment who were initiating HAART and 25 HIV-negative individuals matched for age and education. Depression was assessed using the Centre for Epidemiologic Studies Depression Scale (CES-D). Neurocognitive assessment included the International HIV Dementia Scale (IHDS), an 8 test neuropsychological battery and the Memorial Sloan Kettering scale. Assessments were carried out at 0, 3 and 6 months. Results: The HIV-positive group had more respondents with CES-D score > 16 than the HIV-negative group at all 3 clinic visits (54%Vs 28%; 36% Vs 13%; and 30% Vs 24% respectively; all p < 0.050 OR 2.86, 95% CI: 1.03, 7.95, p = 0.044). The HIV positive group had higher likelihood for cognitive impairment (OR 8.88, 95% CI 2.64, 29.89, p < 0.001). A significant decrease in the mean scores on the CES-D (p = 0.002) and IHDS (p = 0.001) occurred more in the HIVpositive group when compared to the HIV-negative group. There was no association between clinical Memorial Sloan Kettering score and depression symptoms (p = 0.310) at baseline. Conclusion: Depression symptomatology is distinct and common among cognitively impaired HIV patients. Therefore individuals in HIV care should be screened and treated for depression.


Related Articles

  • Changes in condom use during the first year of HIV treatment in Uganda and the relationship to depression. Wagner, Glenn; Ghosh-Dastidar, Bonnie; Slaughter, Mary; Akena, Dickens; Nakasujja, Noeline; Musisi, Seggane; Wagner, Glenn J; Slaughter, Mary Ellen // Annals of Behavioral Medicine;Oct2014, Vol. 48 Issue 2, p175 

    Purpose: We examined the effect of antiretroviral therapy (ART), and the predictive role of depression, on condom use with primary partners.Methods: Data from three studies in Uganda were combined into a sample of 750 patients with a primary sex partner, with 502...

  • Clinician-Assessed Depression and HAART Adherence in HIV-Infected Individuals in Methadone Maintenance Treatment. Gonzalez, Jeffrey S.; Psaros, Christina; Batchelder, Abigail; Applebaum, Allison; Newville, Howard; Safren, Steven A. // Annals of Behavioral Medicine;Aug2011, Vol. 42 Issue 1, p120 

    Background: The impact of measurement methods on the relationship between depression and HIV treatment adherence has not been adequately examined. Purpose: The purpose of this paper is to examine the relationship between clinician- and patient-rated depression and HIV medication adherence....

  • Undertreatment of human immunodeficiency virus in psychiatric inpatients: a cross-sectional study of seroprevalence and associated factors. Gonzalez-Torres, Miguel Angel; Salazar, Miguel Angel; Imaz, Manuel; Inchausti, Lucía; Ibañez, Berta; Fernandez-Rivas, Aranzazu; Pastor, Javier; Anguiano, Bosco; Muñoz, Pedro; Ruiz, Eduardo; Oraa, Rodrigo; Bustamante, Sonia; de Eulate, Sofia Alvarez; Cisterna, Ramón // Neuropsychiatric Disease & Treatment;Jun2015, Vol. 11, p1421 

    Background: The aims of this study were to evaluate the prevalence of HIV and its associated demographic and clinical factors among psychiatric inpatients of a general hospital. Methods: This was a single-center, observational, cross-sectional study that included patients consecutively admitted...

  • Human immunodeficiency virus-associated depression: contributions of immuno-inflammatory, monoaminergic, neurodegenerative, and neurotrophic pathways. Guerra, F.; Fonseca, J.; Figueiredo, V.; Ziff, E.; Konkiewitz, E. // Journal of NeuroVirology;Aug2013, Vol. 19 Issue 4, p314 

    In the era of greatly improved pharmacological treatment of HIV infection through highly active antiretroviral therapy (HAART), HIV patients experience reduced viral loads, reduced opportunistic infections, increased CD4+ T cell count, and greater life expectancy. Although life expectancy is...

  • Screening for Neurocognitive Impairment in HIV Individuals: The Utility of the Montreal Cognitive Assessment Test. Hasbun, Rodrigo; Eraso, Jairo; Ramireddy, Sweeya; Wainwright, D' Arcy; Salazar, Lucrecia; Grimes, Richard; York, Michele; Strutt, Adriana // Journal of AIDS & Clinical Research;2012, Vol. 3 Issue 10, Special section p1 

    The article discusses a study on the use of the Montreal Cognitive Assessment Test in the screening of neurocognitive impairment in HIV-positive people. The study involved a group of patients who received highly active antiretroviral therapy (HAART). Results revealed co-infections among the...

  • Neuropsychological evaluation and follow up in jcv- and non-jcv-related leukoencephalopathies in HIV infection. Zucchella, C.; Sinforiani, E.; Tavazzi, E.; Del Bue, S.; Novati, S.; Maserati, R.; Ceroni, M.; Bastianello, S.; Minoli, L.; Ferrante, P.; Marchioni, E. // Neurological Sciences;Oct2011, Vol. 32 Issue 5, p833 

    The introduction of highly active antiretroviral therapy does not seem to have altered the incidence of progressive multifocal leukoencephalopathy (PML) in HIV infection. Moreover, the occurrence of a HIV-related leukoencephalopathy, called not determined leukoencephalopaties (NDLE), has been...

  • Assessment of neurocognitive functions in HIV/AIDS patients on HAART using the international HIV dementia scale. Saini, Savita; Barar, Kiran V. // International Journal of Nutrition, Pharmacology, Neurological D;Oct-Dec2014, Vol. 4 Issue 4, p252 

    Background: Human immunodeficiency virus (HIV)-infected individuals on National AIDS Control Organization's (NACO)-India-Based-highly active antiretroviral therapy (HAART) regimen often continue experiencing neurological complications, referred to as HIV-associated neurocognitive disorders...

  • Prevention, Rehabilitation, and Mitigation Strategies of Cognitive Deficits in Aging with HIV: Implications for Practice and Research. Vance, David E. // ISRN Nursing;2013, p1 

    Highly active antiretroviral therapy has given the chance to those living with HIV to keep on living, allowing them the opportunity to age and perhaps age successfully. Yet, there are severe challenges to successful aging with HIV, one of which is cognitive deficits. Nearly half of those with...

  • HAART may be effective for HIV epidemic control.  // PharmacoEconomics & Outcomes News;7/24/2010, Issue 608, p4 

    The article discusses research study on the association of highly active antiretroviral therapy, coverage, population viral load and yearly new human immunodeficiency virus (HIV) diagnoses in British Columbia, referencing a study by J. S. G. Montaner and colleagues published in the July 18, 2010...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics